SAN FRANCISCO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Arshad Khanani, MD, MA, FASRS, discusses 2-year results of the GATHER2 trial investigating avacincaptad pegol for geographic atrophy.
According to Khanani, patients treated with avacincaptad pegol every month saw a statistically significant decrease in GA lesion growth compared with sham, while patients dosed every other month saw comparable results.
“When we look at the absolute reduction in GA growth lesion, we see more than doubling of the treatment effect in patients treated with